Korro Bio, Inc.
KRRONext catalyst
KRRO-110
Alpha-1 Anti-trypsin Deficiency
Get an email about KRRO's next catalysts
Track Korro Bio (KRRO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, Phase 2 readout).See the timeline
3 upcoming, 1 past
KRRO Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-1.14 | FQ end Sep/2026 | Call: tbd
KRRO-110 Phase 2 Est. Readout
Primary completion for KRRO-110 trial (NCT06677307) in Alpha-1 Anti-trypsin Deficiency
SourceKRRO-121 Phase 2 Est. Readout (ANCHOR)
Estimated primary completion for KRRO-121 trial (NCT07773246) in Urea Cycle Disorders, Inborn. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Frequently asked questions
What is in Korro Bio, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Korro Bio, Inc.'s (KRRO) pipeline across Phase 2. Its lead program is KRRO-110 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Korro Bio, Inc.'s next FDA catalyst?→
Korro Bio, Inc.'s (KRRO) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KRRO biotech catalysts?→
Add KRRO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Korro Bio, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.